Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$63.58 +0.6%	$61.71	$43.70 ▼ $86.53	$2.02B	-1.5	42,320 shs	125,270 shs
CNTA Centessa Pharmaceuticals	$15.13 +4.9%	$12.94	$9.00 ▼ $19.09	$2.02B	1.45	934,897 shs	2.01 million shs
IRON Disc Medicine	$57.74 +1.5%	$50.05	$30.82 ▼ $68.73	$2.00B	0.76	410,326 shs	235,086 shs
SIGA Siga Technologies	$6.86 +1.3%	$6.20	$4.95 ▼ $12.83	$490.08M	0.94	463,291 shs	371,384 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	0.00%	+5.83%	+6.16%	+7.87%	+28.60%
CNTA Centessa Pharmaceuticals	0.00%	+0.66%	+16.56%	+20.85%	+46.35%
IRON Disc Medicine	0.00%	+3.95%	+5.96%	+41.32%	+20.65%
SIGA Siga Technologies	0.00%	+0.52%	+6.45%	+10.08%	-22.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.0232 of 5 stars	3.5	2.0	2.0	0.8	0.6
CNTA Centessa Pharmaceuticals	3.2439 of 5 stars	3.5	4.0	1.6	3.3	0.6
IRON Disc Medicine	3.2309 of 5 stars	4.5	2.0	2.5	2.5	0.0
SIGA Siga Technologies	2.2349 of 5 stars	0.0	3.0	2.0	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	52.04% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.89	84.33% Upside
IRON Disc Medicine	3.09	Buy	$96.70	67.47% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SIGA, IRON, BLTE, and CNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
7/3/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
7/3/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/16/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
6/11/2025	IRON Disc Medicine	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/15/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
5/12/2025	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $120.00
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$4.72 per share	N/A
CNTA Centessa Pharmaceuticals	$15M	134.71	N/A	N/A	$3.05 per share	4.96
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A
SIGA Siga Technologies	$138.72M	3.53	$0.85 per share	8.09	$3.02 per share	2.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$36.14M	-$1.36	N/A	N/A	N/A	N/A	-32.07%	-30.91%	8/8/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.81	N/A	N/A	N/A	N/A	-40.22%	-29.95%	8/12/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$3.92	N/A	N/A	N/A	N/A	-22.61%	-21.07%	8/6/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$0.67	10.24	5.49	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)

Latest SIGA, IRON, BLTE, and CNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	BLTE Belite Bio	-$0.42	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	24.31	24.31
CNTA Centessa Pharmaceuticals	0.28	14.37	14.37
IRON Disc Medicine	0.04	37.65	37.65
SIGA Siga Technologies	N/A	8.40	6.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
CNTA Centessa Pharmaceuticals	82.01%
IRON Disc Medicine	83.70%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
CNTA Centessa Pharmaceuticals	7.09%
IRON Disc Medicine	4.24%
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
CNTA Centessa Pharmaceuticals	200	133.56 million	124.09 million	Optionable
IRON Disc Medicine	30	34.63 million	33.17 million	Not Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable

SIGA, IRON, BLTE, and CNTA Headlines

Recent News About These Companies

Investors Purchase High Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

July 10, 2025 | americanbankingnews.com

Siga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)

July 10, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why

July 9, 2025 | zacks.com

SIGA Technologies Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

Why Siga Technologies Inc. (SIGA) Outpaced the Stock Market Today

June 26, 2025 | zacks.com

Investors Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

June 26, 2025 | marketbeat.com

New nuclear fuel cladding survive 3,452°F, 6 times hotter than normal reactors

June 25, 2025 | msn.com

General Atomics Achieves Another Milestone in Silicon Carbide Composite Nuclear Fuel Rod Technology

June 24, 2025 | indystar.comI

Here's Why Siga Technologies Inc. (SIGA) Fell More Than Broader Market

June 20, 2025 | zacks.com

Undiscovered Gems In US Market Including SIGA Technologies And 2 Other Small Caps

June 17, 2025 | finance.yahoo.com

Bank of America Corp DE Sells 367,682 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)

June 16, 2025 | marketbeat.com

Why Siga Technologies Inc. (SIGA) Dipped More Than Broader Market Today

June 13, 2025 | zacks.com

We Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster Earnings

May 16, 2025 | finance.yahoo.com

Undiscovered Gems in the US Market for May 2025

May 15, 2025 | finance.yahoo.com

SIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)

May 10, 2025 | finance.yahoo.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2025 Earnings Call Transcript

May 9, 2025 | msn.com

SIGA Reports Financial Results for Three Months Ended March 31, 2025

May 8, 2025 | globenewswire.com

Calculating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

May 2, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for Investors

May 1, 2025 | zacks.com

SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results

May 1, 2025 | globenewswire.com

Chiliz joins SIGA to help drive integrity in sport

April 30, 2025 | en.as.comE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Tech Stocks You Can't Miss in This Market Cycle
By Gabriel Osorio-Mazilli | June 17, 2025
View 3 Tech Stocks You Can't Miss in This Market Cycle
1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
By Gabriel Osorio-Mazilli | July 8, 2025
View 1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
Whiplash for Investors: AeroVironment's Confusing Stock Signals
By Jeffrey Neal Johnson | July 2, 2025
View Whiplash for Investors: AeroVironment's Confusing Stock Signals
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

SIGA, IRON, BLTE, and CNTA Company Descriptions

Belite Bio NASDAQ:BLTE

$63.58 +0.36 (+0.57%)

Closing price 04:00 PM Eastern

Extended Trading

$63.70 +0.12 (+0.19%)

As of 04:03 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Centessa Pharmaceuticals NASDAQ:CNTA

$15.13 +0.70 (+4.85%)

Closing price 04:00 PM Eastern

Extended Trading

$15.11 -0.02 (-0.13%)

As of 04:44 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Disc Medicine NASDAQ:IRON

$57.74 +0.83 (+1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$57.79 +0.05 (+0.09%)

As of 04:07 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Siga Technologies NASDAQ:SIGA

$6.86 +0.09 (+1.33%)

Closing price 04:00 PM Eastern

Extended Trading

$6.88 +0.01 (+0.22%)

As of 07:40 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time